Claims

- 1. An anti-virus agent acting against single stranded RNA (+) viruses, comprising the following components (A) and (B),
 - (A) a nucleotide sequence directing the synthesis of the complementary strand of the single stranded virus;
 - (b) a nucleotide sequence containing at least a regulatory region operably linked to a structural gene encoding a toxin,
- wherein the nucleotide sequence encoding the toxin is positioned in an antisense direction.
 - 2. The anti-virus agent according to claim 1, wherein component (A) is derived from the 5'- and/or 3'-untranslated regions of a ss(+)RNA virus.
 - 3. The anti-virus agent according to claim 2, wherein wherein the component(A) is derived from the 3' untranslated region of the HCV virus.
 - 4. The anti-virus agent according to any of the preceding claims, wherein the regulatory region comprises from the Shine-Dalgarno sequence or the internal ribosomal binding site (IRBS) of the genomic RNA of the poliovirus vaccine strain Sabin 2
 - 5. The anti-virus agent according to any of the preceding claims, wherein the toxin is seleted from the group comprising diphteria exotoxin, diphtheria exotoxin A-subunit, Shigella toxin, Disenteria toxin.
 - 6. The anti-virus agent according to any of the preceding claims, which comprises a DNA or a RNA vector.
- 30 7. Use of an anti-virus agent according to any of the preceding claims for the manufacture of a medicament for treating a viral disease.

25

5

8. The use according to claim 7, wherein the viral disease is caused by a hepatitis virus type B, C, D and or E, the Dengue virus, unclassified flaviviridae, Rubella virus, Yellow fever virus, Dengue virus, bovine viral diarrhoea virus, swine fever virus, footh and mouth disease virus.